Insider · CIK 0001242126
Mark McDade
Files at TRML (Tourmaline Bio, Inc.). First filing -, latest -.
Mark McDade files SEC Form 4 as director at TRML (Tourmaline Bio, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Mark McDade has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 8 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 28, 2025 | TRML Tourmaline Bio, Inc. | UTender of shares Common Stock | -518 | - | - | 0 | Oct 28, 2025 |
| Oct 28, 2025 | TRML Tourmaline Bio, Inc. | UTender of shares Common Stockindirect: By Qiming U.S. Healthcare Fund I,L.P. | -183,177 | - | - | 0 | Oct 28, 2025 |
| Oct 28, 2025 | TRML Tourmaline Bio, Inc. | UTender of shares Common Stockindirect: By Qiming U.S. Healthcare Fund II,L.P. | -110,083 | - | - | 0 | Oct 28, 2025 |
| Oct 28, 2025 | TRML Tourmaline Bio, Inc. | UTender of shares Common Stockindirect: By Qiming U.S. Healthcare Fund III,L.P. | -448,431 | - | - | 0 | Oct 28, 2025 |
| Oct 28, 2025 | TRML Tourmaline Bio, Inc. | DDisposition to issuer Employee Stock Option (Right to Buy)derivative | -20,000 | - | - | 0 | Oct 28, 2025 |
| Oct 28, 2025 | TRML Tourmaline Bio, Inc. | DDisposition to issuer Employee Stock Option (Right to Buy)derivative | -10,000 | - | - | 0 | Oct 28, 2025 |
| Oct 28, 2025 | TRML Tourmaline Bio, Inc. | DDisposition to issuer Employee Stock Option (Right to Buy)derivative | -16,800 | - | - | 0 | Oct 28, 2025 |
| Jun 4, 2025 | TRML Tourmaline Bio, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +16,800 | $0.00 | $0 | 16,800 | Jun 6, 2025 |
Questions about Mark McDade
Answered from the filings on this page, as of the latest one.
Is Mark McDade buying or selling?
Mark McDade has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Mark McDade's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Mark McDade has 0.
Where does Mark McDade file Form 4?
Mark McDade has filed Form 4 at TRML (Tourmaline Bio, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.